A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

Gastrointestinal symptoms in Parkinson's disease

L. L. Edwards, Ronald F. Pfeiffer, Eamonn M.M. Quigley et al. · Movement Disorders · 1991 · 366 citations

Medicine, Clinical Sciences, Neurology +14

Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

Moussa B. H. Youdim, Aviva Gross, J. P. M. Finberg · British Journal of Pharmacology · 2001 · 340 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE

W Birkmayer, Peter Riederer, L Ambrozi et al. · The Lancet · 1977 · 296 citations

Medicine, Neurology, Pharmacotherapy +12

Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with <i>l</i>‐Deprenyl

Peter Riederer, Moussa B. H. Youdim · Journal of Neurochemistry · 1986 · 242 citations

Medicine, Neuroscience, Pharmacology +17

A distribution-free procedure for the statistical analysis of bioequivalence studies.

Dieter Hauschke, V W Steinijans, E Diletti · PubMed · 1990 · 221 citations

Pharmacy, Biostatistics, Bioequivalence +13